Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib Consolidation in Metastatic Breast Cancer
NCT00270413Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Jan 2006
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Sutent with Observation (2 arms). Primary endpoint: Progression Free Survival at 5 months. Started Jan 2006; status: completed.
02
Drugs
sunitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00270413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270413.